Cryogenic systems are investments, not consumables. A cryogenic tank that runs for 20 years. A freezing device in daily clinical use. A monitoring system that cannot fail. The purchase price is only part of the story — often not even the most important part.
Comparing cryogenic systems on list price alone is the same mistake as evaluating cars only by purchase cost without accounting for fuel consumption, maintenance, and residual value.
Total Cost of Ownership (TCO) for cryogenic systems spans three cost categories:
Categories 2 and 3 frequently exceed acquisition costs over the full lifecycle of cryogenic systems.
The largest ongoing cost factor in cryogenic storage is liquid nitrogen. A tank consuming 30% less LN₂ saves, for a typical biobank tank using 10 liters/day:
3 liters LN₂/day × 365 days × 20 years = 21,900 liters LN₂
At an LN₂ price of €0.50/liter (bulk buyer): €10,950 saved over the lifetime of a single tank. For five tanks: €54,750 — more than the purchase price of some cheaper competing devices.
That is the core of the eccentric tank opening design in Consarctic®'s BSD+ and BSF+ series: the smaller evaporation surface reduces baseline LN₂ consumption structurally — not through operational optimization, but through design efficiency built into the hardware.
Cryogenic tanks with thin-walled stainless steel or inferior vacuum insulation lose their vacuum level after 8–12 years — after which LN₂ consumption rises sharply until the device must be replaced.
High-quality Consarctic® tanks (solid stainless steel, multi-layer vacuum insulation) reach service lives of 20+ years with maintenance. That effectively halves the annualized capital cost compared to devices with half the lifespan.
For GMP applications, new devices must be qualified (IQ/OQ/PQ). Anyone replacing a budget device every five years pays this qualification cost five times. Someone buying a quality device once and operating it for 20 years pays it once — plus any requalification for system changes.
Consarctic® delivers IQ/OQ documentation for all devices from a single source, reducing qualification effort.
A sample loss from equipment failure in a biobank or pharmaceutical company has direct and indirect costs:
Some of these costs are difficult to quantify (irreversible patient samples, clinical trial interruptions). Cryogenic systems that minimize these risks are often the lower-cost choice — even when their list price is higher.
Example calculation for a BSD+ mid-size tank, 20-year operation: Acquisition including installation: €15,000–25,000; LN₂ consumption: €7,000–20,000; maintenance and calibration: €5,000–10,000; qualification (IQ/OQ): €3,000–8,000. Total: €30,000–63,000 over 20 years. A less efficient tank: higher LN₂ consumption and earlier replacement investment.
Yes, when downstream costs are included: lower LN₂ use through TC-Aktiv, fewer batch reruns due to reliable protocols, lower qualification costs through supplied documentation, longer service life through robust construction.
Costs vary widely: from a deviation report (several thousand euros in effort) to production shutdown or recall (in the millions). A monitoring system that prevents such events pays for itself in a single avoided incident.
Cryogenic technology is not a consumable purchase. The devices running daily in laboratories, clinics, and biobanks will be in service for 10, 15, or 20 years. What they cost over that time is not determined by list price — it's determined by LN₂ consumption, maintenance intervals, failure risk, and qualification effort.
Consarctic GmbH builds equipment for 20-year operation — and is transparent about what that means for the full cost picture.